2016-03-13T00:00:00.000-05:00
Celgene Co.,-0.12599
earnings results,-0.244428
integrated biopharmaceutical company,0.302063
strong buy rating,0.288035
business’s stock,-0.248935
RBC Capital,0.343107
investment portfolio,0.438044
stock,0.105757
consensus price target,0.486721
Capital Management,0.315988
recent filing,0.525959
Ballentine Partners,0.425135
InvestorPlace Broker Center,0.555736
firm’s stock,-0.203719
research report,0.376271
biopharmaceutical company,0.427845
Ballentine Partners LLC,0.296644
sell rating,0.356433
SEC website,0.489784
personal trading style,0.598412
recent disclosure,0.412326
Investment Group LLC,0.482001
Diversified Trust,0.747977
Crestpoint Capital Management,0.315988
equities research analysts,0.300574
shares,0.197754
Capital Investment Services,0.557497
concise daily summary,0.449296
Michael W. Bonney,-0.203719
Director Gilla Kaplan,-0.248935
stock broker,0.245696
Mariner Investment Group,0.482001
consensus rating,0.496578
new position,0.540487
quarter,0.494346
